NCT07607002Completed
Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 70000 (actual)
- First submitted
- 19 May 2026
- Start date
- 1 Jan 1996
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Arbor Research Collaborative for Health
- Diseases
- IgA nephropathy
- NCT number
- NCT07607002
What you commit to
- Study type: Observational
- Participants enrolled: 70000
- From 1 Jan 1996 to the primary completion date, 31 Dec 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Age ≥ 18 years at the time of enrollment
- Receiving in-center HD treatment at a participating dialysis facility
- Able to provide informed consent, if required by local regulations or ethics boards
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.